Alnylam currently markets four drugs — Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran). Portfolio of Marketed Drugs Boosts Revenues ...

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

Alnylam-Aktie vor starkem Quartal - Amvuttra-Einführung an Fahrt gewinnt: 13.06. Alnylam stock poised for strong quarter as Amvuttra launch gains traction: Firmen im Artikel. 5-Tage-Chart ...

Alnylam plans to file for FDA approval of Amvuttra in ATTR-CM later this year and will use a priority review voucher, which will slice by four months the regulator’s standard 10-month appraisal ...

Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy. − First and Only RNAi Therapeutic Approved by the European ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

Investing.com - BMO Capital raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) stock to $360 from its previous target while maintaining an Outperform rating.

Chardan keeps $325 price target on Alnylam, citing strong Amvuttra launch potential Most of Alnylam’s manufacturing and IP is U.S.-based, easing tariff concerns See how Matt Maley is positioning ...

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR ...

Alnylam Pharmaceuticals has won expanded European Commission approval of its Amvuttra drug for use in a rare and potentially fatal heart condition. The Cambridge, Mass., biopharmaceutical company ...

Alnylam currently markets four drugs — Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran). Portfolio of Marketed Drugs Boosts Revenues ...